Notably, the targeted restoration of GDCA levels has demonstrated therapeutic efficacy in preclinical models, where oral GDCA administration suppressed tumor growth and promoted apoptosis in HCC-bearing mice [71]. The gene discussed is GNAT3; the disease is hepatocellular carcinoma.